

Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

Information Governance Department

Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk

Web: www.wwl.nhs.uk

Ref: FOI/2025/11157

Date Received: 17th October 2025

Response Due: 14th November 2025

Date: 2nd December 2025

Dear Sir/Madam

With reference to your request for information received on 17th October 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold part of the information you have requested. A response to each part of your request is provided below.

In your request you asked:

I would like to raise an FOI request, which I hope you will be able to help me with.

1. **How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of July, August and September (or the latest 3 months available) with the treatments I have provided below?**

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st July 2025, they are not classed as a new patient for the purposes of this question.

| | Total Gastroenterology Department | Crohn's Disease | Ulcerative Colitis |
|-----------------------------|-----------------------------------|-----------------|--------------------|
| Adalimumab [Humira] | 0 | 0 | 0 |
| Adalimumab [All Biosimilar] | 0 | 0 | 0 |
| Etrasimod | 0 | | 0 |

| | | | |
|-------------------------------------|----|----|---|
| Filgotinib | 0 | | 0 |
| Golimumab | 0 | 0 | 0 |
| Infliximab [Remicade] | 0 | 0 | 0 |
| Infliximab [All Biosimilar] | 3 | 2 | 1 |
| Mirikizumab | 0 | 0 | 0 |
| Ozanimod | 0 | | 0 |
| Risankizumab | 3 | 2 | 1 |
| Tofacitinib | 0 | | 0 |
| Upadacitinib | 3 | 1 | 1 |
| Ustekinumab [Stelara] | 0 | 0 | 0 |
| Ustekinumab [All Biosimilar] | 25 | 16 | 8 |
| Vedolizumab | 2 | 2 | 0 |

Internal dispensing data from the Trust's pharmacy could not be fully incorporated into the condition-based analysis because indication data is not recorded in that source.

Therefore, the above figures reflect patients receiving treatment from Homecare only, where indication was available.

Between the 1st July 2025 and 30th September 2025, 36 patients were identified as new starters for the treatments listed via Homecare supply for Gastroenterology, as defined in your request.

Due to the absence of indication data in internal hospital pharmacy systems, it is not possible to provide disease specific analysis for patients treated outside of the Homecare service.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111